Ohm,

Yes. This is precisely what is baffling. The two main differences between Cenicriviroc (CVC) and LL is that the former is a small molecule and, apparently, also suppresses the binding of MCP-1 to CCR2b-expressing cells.

So, there are possibly two targets: either CCR5 or CCR2b, however if MCP-1 goes up it does not raise hopes for "modulating the immune response" , which is exactly what the ACTIV study is trying to achieve.

Unless "modulation" means "increasing the cytokine storm".

Quote:

---

The National Institutes of Health has launched an adaptive Phase 3 clinical trial to evaluate the safety and efficacy of three immune modulator drugs in hospitalized adults with COVID-19. Some COVID-19 patients experience an immune response in which the immune system unleashes excessive amounts of proteins that trigger inflammation — called a “cytokine storm” — that can lead to acute respiratory distress syndrome, multiple organ failure and other life-threatening complications. The clinical trial aims to determine if modulating that immune response can reduce the need for ventilators and shorten hospital stays. The trial, known as ACTIV-1 Immune Modulators (IM), will determine if the therapeutics are able to restore balance to an overactive immune system.

---

NP should request Leronlimab to be taken into account for these studies. ANY venue to get LL out there is valid and more with government sponsorship.